Myomo, Inc. (MYO)
NYSE American · Healthcare · Medical Devices
$1.67+2.45%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $66.2M
- 52-week range
- $0.605 – $1.89
- 52-week change
- +55.24%
- EPS (trailing)
- −$0.35
- Next earnings
- Nov 9, 2026
Fiscal year to Dec 2025
- Revenue
- $40.9M (+25.74%)
- Net income
- −$15.6M
- Operating margin
- −35.2%
- Diluted EPS
- −$0.37
- Free cash flow
- −$16.3M
From the company’s annual report on SEC EDGAR.
About Myomo, Inc.
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the brace; MyoPro2+, which comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device; MyoGames, a virtual training platform; and MyoPro 2x Video Library. In addition, the company offers MyoCare, a post-delivery program that provides follow-up care with clients, therapists, and referral sources; MYOMO; MyoPal; and MyoCoach. Its products are designed to help adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders.
Headquarters: Burlington, United States · 194 employees · myomo.com